PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
199874-0	1977	Response of gonadotropins to stimulation with luteinizing hormone -- releasing hormone (LH-RH) in children with precocious puberty before, during and following therapy with cyproterone acetate or an ethisterone derivate.	Cyproterone Acetate	173-192	gonadotropin releasing hormone 1	Homo sapiens	88-93	
2853934-10	1988	This study suggests that all patients receiving GnRH agonist treatment should be pretreated with cyproterone acetate 100 mg three times daily for 1 week before implantation and for the first treatment month.	Cyproterone Acetate	97-116	gonadotropin releasing hormone 1	Homo sapiens	48-52	
328285-0	1977	The LH and FSH responses to LH-releasing hormone (LH-RH) in girls with true precocious puberty treated with cyproterone acetate.	Cyproterone Acetate	108-127	gonadotropin releasing hormone 1	Homo sapiens	28-48	
328285-0	1977	The LH and FSH responses to LH-releasing hormone (LH-RH) in girls with true precocious puberty treated with cyproterone acetate.	Cyproterone Acetate	108-127	gonadotropin releasing hormone 1	Homo sapiens	50-55	
6215543-0	1982	[The response to gonadotropin-releasing hormone in hirsutism after treatment with cyproterone acetate].	Cyproterone Acetate	82-101	gonadotropin releasing hormone 1	Homo sapiens	17-47	
12927003-11	2003	Patients previously treated with other agents like CPA, MPA, or SSRIs reported better effects when taking LHRH agonists.	Cyproterone Acetate	51-54	gonadotropin releasing hormone 1	Homo sapiens	106-110	
11224953-5	2001	In combination with other treatments, LHRH Agonists seem to be a very promising alternative to cyproterone acetate and its possible carcinogene effects.	Cyproterone Acetate	95-114	gonadotropin releasing hormone 1	Homo sapiens	38-42	
8821690-6	1996	It is concluded that total androgen ablation using cyproterone acetate (300 mg/day) and goserelin acetate (3.6 mg every 28 days) confers no advantage in terms of time to progression, to conventional monotherapy, but can reduce certain side effects caused by LHRH analogue treatment alone.	Cyproterone Acetate	51-70	gonadotropin releasing hormone 1	Homo sapiens	258-262	
8557156-11	1996	CONCLUSION: Gonadotropin-releasing hormone agonist, associated with a pill containing CPA, reduced the hirsutism in severely affected women with PCOD who are unresponsive to OC treatment alone.	Cyproterone Acetate	86-89	gonadotropin releasing hormone 1	Homo sapiens	12-42	
7864578-8	1994	We studied the efficacy of a GnRH analogue (Triptoreline), which induces a reversible hormonal castration and of which both the formulation and the route of administration avoid the inconveniences linked to a treatment with cyproterone acetate.	Cyproterone Acetate	224-243	gonadotropin releasing hormone 1	Homo sapiens	29-33